fatnews.com Fatnews Bitchute Channel Link Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Belviq (lorcaserin) increases risk of mitral regurgitation 2-fold


    Posted by .(JavaScript must be enabled to view this email address)
    Saturday, November 01, 2014 12:34 pm Email this article

    Belviq (lorcaserin), a weight loss drug, was associated with a 2-fold increased risk of moderate or greater mitral regurgitation after one-year of drug use according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

    “Despite the fact that the lorcaserin package insert states that it does not cause a significant increase in FDA-defined valvulopathy, defined as mitral regurgitation greater than mild or aortic regurgitation greater than trace (pooled relative risk (RR) of the phase 3 echocardiographic data: 1.16; 95% CI 0.81 to 1.67), a look at the FDA Medical Review states that lorcaserin causes a significant increase in moderate or greater mitral regurgitation at week 52 (RR 1.95; 95% CI 1.05 to 3.59, p value not stated) and (RR 1.88; 95% CI 1.02 to 3.47, p=0.04) based on our forest plot) (figure 1),” the paper notes.

    “These data were based on a meta-analysis of three randomised controlled trials testing lorcaserin 10 mg twice daily versus placebo.”

    Reference

    DiNicolantonio JJ, Chatterjee S, O’Keefe JH, and Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart, 2014; 1(1): http://openheart.bmj.com/content/1/1/e000173.full.

    Author’s Contact Info

    James J. DiNicolantonio, PharmD
    Associate Editor BMJ Open Heart
    Cardiovascular Research Scientist
    Saint Luke’s Mid America Heart Institute
    http://www.saintlukeshealthsystem.org/dinicolantonio
    https://www.researchgate.net/profile/James_Dinicolantonio
    https://twitter.com/jjdinicol
    .(JavaScript must be enabled to view this email address)

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.